Effectiveness of a Synergistic, Neuroplasticity-Based intervention for Rapid and Durable Suicide Risk Reduction

基于神经可塑性的协同干预措施对快速、持久降低自杀风险的有效性

基本信息

  • 批准号:
    10684238
  • 负责人:
  • 金额:
    $ 63.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-15 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary. Intravenous ketamine, which displays rapid antidepressant and anti-suicidality properties, is posited to reverse symptoms by rapidly enhancing neuroplasticity; but surprisingly little is known regarding its feasibility, safety, and effectiveness for reducing suicidal outcomes among real-world, heterogenous samples at imminent risk. Furthermore, a significant barrier to clinical adoption is the lack of evidence for durability of ketamine's effects, raising concerns about illusory recovery and subsequent rebound of suicide risk. We posit that ketamine will rapidly decrease suicidal ideation and rapidly increase cognitive flexibility in a real-world sample, allowing for rigid, negative biases in cognition to be rapidly reversed. We further expect these neurocognitive changes will provide a clinical window of opportunity in which to introduce 1) standard crisis-oriented psychiatric care; and 2) automated cognitive training (CT) techniques, which will consolidate adaptive forms of cognitive processing (specifically, positive and life-oriented implicit representations of self) while neuroplasticity remains high. Instantiating adaptive forms of processing (through standard care and/or automated CT) after first 'priming' the brain with ketamine represents a potentially synergistic treatment approach that could extend the acute effects of a single ketamine infusion beyond its typical 3-7 day window, efficiently fostering protective anti- suicidal effects that are both rapid and enduring. In this study, 200 Medical Unit inpatients (age 18-65) will be enrolled by referral from the psychiatric consultation/liaison service in a large Level 1 trauma hospital, following consult for a medically serious suicide attempt (SA). Leveraging medical unit physicians who are well-accustomed to utilizing ketamine infusion routinely in their inpatient medical settings, inpatients will be randomized in a parallel arm design to receive a single infusion of ketamine “pre-treatment”—shortly prior to subsequent psychiatric inpatient stay—or no- infusion. Patients will complete acute measures of explicit SI and cognitive target engagement (implicit suicide-self associations; Aim 1). In a fully crossed (2 x 2 factorial), parallel arm design, patients will then be randomized to receive a brief web-app-based cognitive training protocol during the post-infusion "window of opportunity," designed to implicitly reverse negative self-representations, instilling beneficial self-representations in their place, or a sham variant of the same training. Patients, investigators, and outcome raters will be blinded to treatment condition. Comprehensive feasibility/safety data will be captured for both intervention components. Remote assessments and the medical record will then be used to capture SI and SAs over a 12-month naturalistic follow-up to assess whether: ketamine followed by standard psychiatric inpatient care has a beneficial impact over no-infusion standard-of-care (Aim 2) and active cognitive training enhances and/or extends the durability of ketamine's effects, potentially providing an exceedingly efficient, low- cost, portable, non-invasive, safe, and highly dissemination-ready strategy (Aim 3). This study will provide novel feasibility, safety, and effectiveness data on ketamine's impact among heterogeneous real-world patients at imminent risk of suicide, and will represent a first attempt to synergistically combine ketamine with both standard and novel (cognitive training) interventions in a real-world, generalizable setting, in an effort to exploit and extend ketamine's rapid effects.
项目摘要。静脉注射氯胺酮,它显示出快速的抗抑郁和抗自杀特性,被认为是 通过快速增强神经可塑性来逆转症状;但令人惊讶的是,关于其可行性,安全性, 以及在现实世界中降低自杀结果的有效性,异质性样本在迫在眉睫的风险。此外,委员会认为, 临床采用的一个重大障碍是缺乏氯胺酮效果持久性的证据,这引起了人们对以下问题的担忧: 虚幻的恢复和随后的自杀风险反弹。我们认为氯胺酮会迅速减少自杀意念 并迅速增加现实世界样本中的认知灵活性,允许认知中的刚性,负面偏见, 迅速逆转。我们进一步预计,这些神经认知变化将提供一个临床机会窗口, 引入1)标准的以危机为导向的精神病护理; 2)自动认知训练(CT)技术, 巩固认知处理的适应性形式(具体而言,积极和面向生活的自我内隐表征) 而神经可塑性仍然很高。实例化自适应形式的处理(通过标准护理和/或自动化处理) CT)在首次用氯胺酮“启动”大脑后,代表了一种潜在的协同治疗方法, 单次氯胺酮输注的急性效应超过其典型的3-7天窗口,有效地促进保护性抗- 自杀的影响是迅速和持久的。在本研究中,将招募200名医疗单位住院患者(年龄18-65岁), 一家大型一级创伤医院的精神科咨询/联络服务处转介, 严重自杀企图(SA)。利用医疗单位的医生谁是习惯于利用 在住院医疗环境中常规输注氯胺酮,住院患者将以平行组设计随机分配, 接受单次氯胺酮“预治疗”-在随后的精神病住院治疗前不久-或不接受- 输液患者将完成外显SI和认知目标参与(内隐自杀自我)的急性测量 关联;目标1)。在完全交叉(2 x 2析因)、平行组设计中,患者将随机接受 在输注后“机会之窗”期间,简短的基于网络应用程序的认知训练方案,旨在隐含 扭转消极的自我表征,灌输有益的自我表征,或相同的虚假变体 训练患者、研究者和结局评定者将对治疗状况保持盲态。全面 将采集两种干预成分的可行性/安全性数据。远程评估和医疗记录将 然后在12个月的自然随访中用于捕获SI和SA,以评估是否:氯胺酮,然后 标准的精神病住院治疗对无输液标准治疗(目标2)和积极认知 训练增强和/或延长氯胺酮作用的持久性,潜在地提供一种非常有效的,低- 成本低、便携、非侵入性、安全和高度传播准备策略(目标3)。这项研究将提供新的 氯胺酮在面临迫在眉睫风险的异质性现实世界患者中影响的可行性、安全性和有效性数据 的自杀,并将代表协同联合收割机氯胺酮与标准和新的(认知 培训)在现实世界中的干预,普遍设置,努力利用和扩大氯胺酮的快速效果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rebecca Price其他文献

Rebecca Price的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rebecca Price', 18)}}的其他基金

Effectiveness of a Synergistic, Neuroplasticity-Based intervention for Rapid and Durable Suicide Risk Reduction
基于神经可塑性的协同干预措施对快速、持久降低自杀风险的有效性
  • 批准号:
    10264902
  • 财政年份:
    2020
  • 资助金额:
    $ 63.68万
  • 项目类别:
Experimental Manipulation of OFC Function and Behavioral Context: Towards an Integrative Translational Model of Compulsive Behaviors
OFC 功能和行为背景的实验操作:建立强迫行为的综合转化模型
  • 批准号:
    10094322
  • 财政年份:
    2020
  • 资助金额:
    $ 63.68万
  • 项目类别:
Experimental Manipulation of OFC Function and Behavioral Context: Towards an Integrative Translational Model of Compulsive Behaviors
OFC 功能和行为背景的实验操作:建立强迫行为的综合转化模型
  • 批准号:
    10678859
  • 财政年份:
    2020
  • 资助金额:
    $ 63.68万
  • 项目类别:
Experimental Manipulation of OFC Function and Behavioral Context: Towards an Integrative Translational Model of Compulsive Behaviors
OFC 功能和行为背景的实验操作:建立强迫行为的综合转化模型
  • 批准号:
    10264883
  • 财政年份:
    2020
  • 资助金额:
    $ 63.68万
  • 项目类别:
Effectiveness of a Synergistic, Neuroplasticity-Based intervention for Rapid and Durable Suicide Risk Reduction
基于神经可塑性的协同干预措施对快速、持久降低自杀风险的有效性
  • 批准号:
    10471401
  • 财政年份:
    2020
  • 资助金额:
    $ 63.68万
  • 项目类别:
Experimental Manipulation of OFC Function and Behavioral Context: Towards an Integrative Translational Model of Compulsive Behaviors
OFC 功能和行为背景的实验操作:建立强迫行为的综合转化模型
  • 批准号:
    10452669
  • 财政年份:
    2020
  • 资助金额:
    $ 63.68万
  • 项目类别:
Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition
测试针对抑郁神经认知的基于神经可塑性的协同干预措施
  • 批准号:
    9376450
  • 财政年份:
    2017
  • 资助金额:
    $ 63.68万
  • 项目类别:
Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition
测试针对抑郁神经认知的基于神经可塑性的协同干预措施
  • 批准号:
    9796295
  • 财政年份:
    2017
  • 资助金额:
    $ 63.68万
  • 项目类别:
Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition
测试针对抑郁神经认知的基于神经可塑性的协同干预措施
  • 批准号:
    10201427
  • 财政年份:
    2017
  • 资助金额:
    $ 63.68万
  • 项目类别:
Testing the causal role of orbitofrontal cortex in human compulsive behavior: a non-invasive brain stimulation study
测试眶额皮质在人类强迫行为中的因果作用:一项非侵入性脑刺激研究
  • 批准号:
    9292806
  • 财政年份:
    2017
  • 资助金额:
    $ 63.68万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 63.68万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 63.68万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 63.68万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 63.68万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 63.68万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 63.68万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 63.68万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 63.68万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 63.68万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 63.68万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了